Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Brachial neuritis following quadrivalent human papilloma virus (HPV) vaccination.

Taras JS, King JJ, Jacoby SM, McCabe LA.

Hand (N Y). 2011 Dec;6(4):454-6. doi: 10.1007/s11552-011-9351-7. Epub 2011 Aug 2. No abstract available.

2.

Brachial plexus neuritis following HPV vaccination.

Debeer P, De Munter P, Bruyninckx F, Devlieger R.

Vaccine. 2008 Aug 18;26(35):4417-9. doi: 10.1016/j.vaccine.2008.06.074. Epub 2008 Jul 3.

PMID:
18602437
3.

Effect of Quadrivalent Human Papillomavirus Vaccination on Oral Squamous Cell Papillomas.

Cyrus N, Blechman AB, Leboeuf M, Belyaeva EA, de Koning MN, Quint KD, Stern JJ.

JAMA Dermatol. 2015 Dec 1;151(12):1359-1363. doi: 10.1001/jamadermatol.2015.2805.

PMID:
26332141
4.

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S, Alvarez FB, Barr E.

Pediatr Infect Dis J. 2007 Mar;26(3):201-9.

PMID:
17484215
5.

Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.

Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E.

Arch Med Res. 2009 Aug;40(6):503-13. doi: 10.1016/j.arcmed.2009.08.004.

PMID:
19853192
6.

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.

Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E.

Vaccine. 2007 Jun 21;25(26):4931-9. Epub 2007 Apr 20.

PMID:
17499406
7.

Human papilloma virus vaccination induces strong human papilloma virus specific cell-mediated immune responses in HIV-infected adolescents and young adults.

Rainone V, Giacomet V, Penagini F, Fabiano V, Calascibetta F, Mameli C, Pisanelli S, Zuccotti GV, Clerici M, Trabattoni D.

AIDS. 2015 Mar 27;29(6):739-43. doi: 10.1097/QAD.0000000000000597.

PMID:
25849837
8.

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.

Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M.

Lancet Infect Dis. 2012 Oct;12(10):781-9. doi: 10.1016/S1473-3099(12)70187-1. Epub 2012 Aug 22. Review.

PMID:
22920953
9.

On the relationship between human papilloma virus vaccine and autoimmune diseases.

Pellegrino P, Carnovale C, Pozzi M, Antoniazzi S, Perrone V, Salvati D, Gentili M, Brusadelli T, Clementi E, Radice S.

Autoimmun Rev. 2014 Jul;13(7):736-41. doi: 10.1016/j.autrev.2014.01.054. Epub 2014 Jan 24. Review.

PMID:
24468416
10.

Cost-effectiveness of different human papillomavirus vaccines in Singapore.

Lee VJ, Tay SK, Teoh YL, Tok MY.

BMC Public Health. 2011 Mar 31;11:203. doi: 10.1186/1471-2458-11-203.

11.
13.

Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus.

Brinth LS, Pors K, Theibel AC, Mehlsen J.

Vaccine. 2015 May 21;33(22):2602-5. doi: 10.1016/j.vaccine.2015.03.098. Epub 2015 Apr 14.

PMID:
25882168
14.

Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years.

Soybilgic A, Onel KB, Utset T, Alexander K, Wagner-Weiner L.

Pediatr Rheumatol Online J. 2013 Aug 7;11:29. doi: 10.1186/1546-0096-11-29. eCollection 2013.

15.

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP).

MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.

16.

Adverse events following HPV vaccination, Alberta 2006-2014.

Liu XC, Bell CA, Simmonds KA, Svenson LW, Russell ML.

Vaccine. 2016 Apr 4;34(15):1800-5. doi: 10.1016/j.vaccine.2016.02.040. Epub 2016 Feb 26.

17.

Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation.

Insinga RP, Dasbach EJ, Allen SE, Carides GW, Myers ER.

Value Health. 2008 Dec;11(7):1022-32. doi: 10.1111/j.1524-4733.2008.00342.x. Epub 2008 May 16.

18.

Why are U.S. girls getting meningococcal but not human papilloma virus vaccines? Comparison of factors associated with human papilloma virus and meningococcal vaccination among adolescent girls 2008 to 2012.

Perkins RB, Lin M, Silliman RA, Clark JA, Hanchate A.

Womens Health Issues. 2015 Mar-Apr;25(2):97-104. doi: 10.1016/j.whi.2014.12.005.

PMID:
25747517
19.

Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhatunewa ED, de Vrij EL, Nijman HW, Daemen T, Wilschut JC, Postma MJ.

BMC Infect Dis. 2013 Feb 7;13:75. doi: 10.1186/1471-2334-13-75.

20.

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease.

Lacey CJ, Lowndes CM, Shah KV.

Vaccine. 2006 Aug 31;24 Suppl 3:S3/35-41. Review.

PMID:
16950016

Supplemental Content

Support Center